A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer-Reference-Cited by-同舟云学术

A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer

Published:2023-11 Issue: Volume:178 Page:110-118
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Han Sileny N.,Oza Amit,Colombo Nicoletta,Oaknin Ana,Raspagliesi Francesco,Wenham Robert M.,Braicu Elena Ioana,Jewell Andrea,Makker Vicky,Krell Jonathan,Alía Eva María Guerra,Baurain Jean-François,Su Zhenqiang,Neuwirth Rachel,Vincent Sylvie,Sedarati Farhad,Faller Douglas V.,Scambia Giovanni

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference38 articles.

1. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study;McMeekin;Gynecol. Oncol.,2007

2. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up;Colombo;Radiother. Oncol.,2015

3. Cancer Stat Facts: Uterine Cancer;NIC,2016

4. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer;Homesley;Int. J. Clin. Oncol.,2008

5. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study;Lincoln;Gynecol. Oncol.,2003

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locally advanced and metastatic endometrial cancer: Current and emerging therapies;Cancer Treatment Reviews;2024-09

2. Development of Mutated β-catenin Gene Signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC;JHEP Reports;2024-08

3. Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway;Cancers;2024-05-14

4. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06